IP Library › Granted Patent US 12,364,709
Granted Patent B2
US 12,364,709 · App. 17/808,174 · Granted Jul 22, 2025

Bioavailable poly amines

Inventor: Mark R. Burns (Epsom, NH)
Assignee: Aminex Therapeutics, Inc.
A61K31/785A61K9/2054A61K9/2846A61K9/2886A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,364,709
App. No.
17/808,174
Granted
Jul 22, 2025
Kind
B2
Abstract

Disclosed herein are pharmaceutical salts of a cationic protonated polyamine pharmaceutical agent and an anionic organic carboxylate which is hydrophobic when in protonated form, particularly suited for oral administration, where these salts have good bioavailability in solid dosage forms and may be used in the treatment of cancer and other medical conditions for which the pharmaceutical agent is intended.

Claims (8)

1. A salt, of spermidine:(capric acid) 3 .

2. A composition comprising a salt of claim 1 and a pharmaceutically acceptable inert component.

3. The composition of claim 2 , in a solid oral dosage form.

4. A method of inducing autophagy, comprising administering to a subject in need thereof a therapeutically effective amount of a salt of claim 1 .

5. The method of claim 4 , wherein the salt is orally administered.

6. A method of inhibiting an effect of aging, comprising administering to a subject in need thereof a therapeutically effective amount of a salt of claim 1 .

7. The method of claim 6 , wherein the salt is orally administered.

8. The salt of claim 1 having chemical structure (II)

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2022
From: BURNS, MARK R.
To: AMINEX THERAPEUTICS, INC.
Reel/Frame 060296/0359 →
Continuity (4)
Continuation 16823150 · Mar 18, 2020
Continuation 15753291
Provisional Application 62313657 · Mar 25, 2016
Related Publication 20230088829A1 · Mar 23, 2023
References Cited (400)
US 4309442A · Bey · 1982 [cited by applicant]
US 4590288A · Klemann · 1986 [cited by applicant]
US 4774339A · Haugland · 1988 [cited by applicant]
US 4818770A · Weinstein · 1989 [cited by applicant]
US 4950744A · Dattagupta · 1990 [cited by applicant]
US 5187288A · Kang · 1993 [cited by applicant]
US 5248782A · Haugland · 1993 [cited by applicant]
US 5252714A · Harris · 1993 [cited by applicant]
US 5274113A · Kang · 1993 [cited by applicant]
US 5433896A · Kang · 1995 [cited by applicant]
US 5451663A · Kang · 1995 [cited by applicant]
US 5541230A · Basu et al. · 1996 [cited by applicant]
US 5648394A · Boxall et al. · 1997 [cited by applicant]
US 5654287A · Prakash · 1997 [cited by applicant]
US 5656671A · Bergeron, Jr. · 1997 [cited by applicant]
US 6172261B1 · Vermeulin et al. · 2001 [cited by applicant]
US 6235737B1 · Styczynski · 2001 [cited by applicant]
US 6646149B1 · Vermeulin et al. · 2003 [cited by applicant]
US 6743419B1 · Shander et al. · 2004 [cited by applicant]
US 6872852B2 · Burns · 2005 [cited by applicant]
US 6914079B2 · Burns et al. · 2005 [cited by applicant]
US 6963010B2 · Burns et al. · 2005 [cited by applicant]
US 7144920B2 · Burns et al. · 2006 [cited by applicant]
US 7160923B1 · Vermeulin et al. · 2007 [cited by applicant]
US 7199267B1 · Burns et al. · 2007 [cited by applicant]
US 7208528B1 · Vermeulin et al. · 2007 [cited by applicant]
US 7388112B2 · Burns et al. · 2008 [cited by applicant]
US 7411002B2 · Burns et al. · 2008 [cited by applicant]
US 7432302B2 · Burns et al. · 2008 [cited by applicant]
US RE43327E · Burns et al. · 2012 [cited by applicant]
US 8258186B2 · McKearn et al. · 2012 [cited by applicant]
US 8609734B2 · McKearn et al. · 2013 [cited by applicant]
US 10632145B2 · Burns · 2020 [cited by applicant]
US 11395834B2 · Burns et al. · 2022 [cited by applicant]
US 11865095B2 · Burns · 2024 [cited by applicant]
US 20030187276A1 · Burns et al. · 2003 [cited by applicant]
US 20050176828A1 · Burns et al. · 2005 [cited by applicant]
US 20050245615A1 · Burns et al. · 2005 [cited by applicant]
US 20060122279A1 · Burns et al. · 2006 [cited by applicant]
US 20090318847A1 · Sebree et al. · 2009 [cited by applicant]
US 20110027172A1 · Wang et al. · 2011 [cited by applicant]
US 20110256161A1 · Burns et al. · 2011 [cited by applicant]
US 20150038512A1 · Looper et al. · 2015 [cited by applicant]
US 20190008892A1 · Burns · 2019 [cited by applicant]
US 20200352983A1 · Burns · 2020 [cited by applicant]
US 20220096412A1 · Burns et al. · 2022 [cited by applicant]
US 20230321012A1 · Burns et al. · 2023 [cited by applicant]
EP 1085011A1 · 2001 [cited by applicant]
GB 1041596 · 1966 [cited by applicant]
JP 02256656A · 1990 [cited by applicant]
JP 09235271 · 1997 [cited by applicant]
JP 2004529082A · 2004 [cited by applicant]
JP 2008519856A · 2008 [cited by applicant]
JP 2011524901A · 2011 [cited by applicant]
KR 100859929B1 · 2008 [cited by applicant]
WO WO1985002769A1 · 1985 [cited by applicant]
WO WO1991000853A1 · 1991 [cited by applicant]
WO WO1992014709A2 · 1992 [cited by applicant]
WO WO1995021612A2 · 1995 [cited by applicant]
WO WO1996022926A1 · 1996 [cited by applicant]
WO WO1996038464A1 · 1996 [cited by applicant]
WO WO1997033560A1 · 1997 [cited by applicant]
WO WO1999003823A2 · 1999 [cited by applicant]
WO WO1999054283A1 · 1999 [cited by applicant]
WO WO2000034226A1 · 2000 [cited by applicant]
WO WO2000046187A2 · 2000 [cited by applicant]
WO WO2001072685A2 · 2001 [cited by applicant]
WO WO2002053519A2 · 2002 [cited by applicant]
WO WO2007001455A2 · 2007 [cited by applicant]
WO WO2009154648A1 · 2009 [cited by applicant]
WO WO2017165313A1 · 2017 [cited by applicant]
WO WO2022072586A1 · 2022 [cited by applicant]
WO 2023102402A1 · 2023 [cited by applicant]
Berge et al., J. Pharm. Sci. 1977, vol. 66 1-18. [cited by examiner]
Advisory Action for U.S. Appl. No. 11/050,789, titled: “Hydrophobic Polyamine Analogs And Methods For Their Use,” mailed Oct. 3, 2007. [cited by applicant]
Advisory Action for U.S. Appl. No. 11/062,481, titled: “Hydrophobic Polyamine Analogs And Methods For Their Use,” mailed Mar. 14, 2008. [cited by applicant]
Ajani, J.A., et al. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. Cancer Chemother Pharmacol 26, 223-226 (1990). [cited by applicant]
Ajani, J.A., Ota, D.M., Grossie, V.B., Jr., Levin, B. & Nishioka, K. Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia wi… [cited by applicant]
Albanese, L., et al., “Investigations of the Mechanism by which Mammalian Cell Growth is Inhibited b N [cited by applicant]
Alberts, D.S., et al. Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev 9, 1281-1286 (2000). [cited by applicant]
Alhohen-Hongisto, L et al., “Tumourigenicity, Cell-Surface Glycoprotein Changes and Ornithine Decarbboxylase Gene Pattern in Ehrlich Ascites-Carcinoma Cells,” Biochem J., 229: 711-715 (1985). [cited by applicant]
Alhonen-Hongisto, L., et al., “Intracellular Putrescine Deprivation Induces Uptake of the Natural Polyamines and Methylglyoxal Bis(Guanylhydrazone),” Biochem. J. 192: 941-945 (1980). [cited by applicant]
Amidon, G.L., et al., “A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability”, Pharm Res 12, 413-420 (1995). [cited by applicant]
Ask, A., et al., “Increased Survival of L1210 Leukemic Mice by Prevention of the Utilization of Extracellular Polyamines. Studies Using a Polyamine-Uptake Mutant, Antibiotics and a Polyamine-Deficient Diet,” Cancer Lett… [cited by applicant]
Atwell, G., et al. “Potential antitumor agents. 45. Synthesis, DNA-binding interaction, and biological activity of triacridine derivatives,” J. Med. Chem., 29(1): 69-74 (1986). [cited by applicant]
Baguley, B.C., “Dna Intercalating Anti-Tumour Agents,” Anti-Cancer Drug Design, 6: 1-35 (1991). [cited by applicant]
Baillon, et al., “Inhibition of mammalian spermine synthase by N-alkylated-1,3-diaminopropane derivatives in vitro and in cultured rat hepatoma cells,” Eur. J. Biochem., vol. 179, pp. 17-21 (1989). [cited by applicant]
Baker, N., Alsford, S. & Horn, D. Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6. Mol Biochem Parasitol 176, 55-57 (2011). [cited by applicant]
Balasundaram, D., et al., “Polyamine-DNA Nexus: Structural Ramifications and Biological Implications,” Mal. Cell. Biochem., 100: 129-40 (1991). [cited by applicant]
Bardocz, S., et al., “Polyamines in food; Implications for Growth and Health,” J Nutr. Biochem., 4: 66-71 (1993). [cited by applicant]
Bauer, et al., “Nitric Oxide Inhibits Ornithine Decarboxylase via S-Nitrosylation of Cysteine 360 in the Active Site of the Enzyme,” The Journal of Biological Chemistry, vol. 276, No. 37, pp. 34458-34464 (2001). [cited by applicant]
Baze, et al., “Distribution of polyamines in human epidermis,” British Journal of Dermatology, vol. 112, pp. 393-396 (1985). [cited by applicant]
Bello-Fernandez, C. & Cleveland, J.L. c-myc transactivates the ornithine decarboxylase gene. Curr Top Microbiol Immunol 182, 445-452 (1992). [cited by applicant]
Bello-Fernandez, C., et al., “The ornithine decarboxylase gene is a transcriptional target of c-Myc”, Proc Natl Acad Sci U S A 90, 7804-7808 (1993). [cited by applicant]
Benaouda, F., et al. “Ion-Pairing with Spermine Targets Theophylline To the Lungs via the Polyamine Transport System”, Mol Pharm 15, 861-870 (2018). [cited by applicant]
Bergeron, R.J. et al., “Total Synthesis (+)-15-Deoxyspergualin,” J. Org. Chem., vol. 57; 1700-3 (1987). [cited by applicant]
Bergeron, R.J., et al., “Reagents for the Stepwise Functionalization of Spermine,”J. Org. Chem, 53: 3108-11 (1988). [cited by applicant]
Bergeron, R.J., et al., “A Comparison of Structure-Activity Relationships between Spermidine and Spermine Analogue Antineoplastics,” J. Med. Chem., 40: 1475-94 (1997). [cited by applicant]
Bergeron, R.J., et al., “Antiproliferative Properties of Polyamine Analogues: A Structure-Activity Study,” J. Med. Chem., 37: 3464:76 (1994). [cited by applicant]
Bey, et al., “α-(Fluoromethyl)dehydroornithine and α-(Fluoromethyl)dehydroputrescine Analogues as Irreversible Inhibitors of Ornithine Decarboxylase,” J. Med. Chem, vol. 26, pp. 1551-1556 (1983). [cited by applicant]
Bey, et al., Analogues of Ornithine as Inhibitors of Ornithine Decarboxylase. New Deductions Concerning the Topography of the Enzyme's Active Site, Journal of Medicinal Chemistry, vol. 21 No. 1, pp. 50-55 (1978). [cited by applicant]
Bey, et al., Inhibition of Basic Amino Acid Decarboxylases Involved in Polyamine Biosynthesis, Sjoerdsma Academic Press, pp. 1-31 (1987). [cited by applicant]
Bhargava, P., et al. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin Cancer Res 7, 3912-3919 (2001). [cited by applicant]
Bitonti, A.J., Bacchi, C.J., McCann, P.P. & Sjoerdsma, A. Uptake of alpha-difluoromethylornithine by Trypanosoma brucei brucei. Biochem Pharmacol 35, 351-354 (1986). [cited by applicant]
Blagbrough, I.S., et al., “Arthropod toxins as leads for novel insecticides: as assessment of polyamine amides as glutamate antagonists,” Toxicon, vol. 30, No. 3: 303-22 (1992). [cited by applicant]
Blagbrough, I.S., et al., “Asymmetric intercalation of N1-(acridin-9-ylcarbonyl)spermine at homopurine sites of duplex DNA,” Chem. Commun., 929-930 (1998). [cited by applicant]
Blagbrough, I.S., et al., “Measurement of polyamine pKa values”, Methods Mal. Biol. 2011, 720, 493-503. [cited by applicant]
Blagbrough, I.S., et al., “Practical Synthesis of the Putative Polyamine Spider Toxin FTX: a Proposed Blocker of Voltage-Sensitive Calcium Channels,” Tetrahedron Lett., 35(13): 2057-60 (1994). [cited by applicant]
Blagbrough, I.S., et al., “Practical Synthesis of Unsymmetrical Polyamine Amides,” Tetrahedron Lett, 39: 439-442 (1998). [cited by applicant]
Bogle, R.G., et al., “Endothelial Polyamine Uptake: Selective Stimulation by L-arginine Deprivation,” Am J Physiol, 266: C776-C783 (1994). [cited by applicant]
Bonaiuto E. et al., “Novel polyamine analogues: From substrates towards potential inhibitors of monoamine oxidases”, Eur. J. Med. Chem., 70:88-101 (2013). [cited by applicant]
Boncher, T. et al. “Polyamine-based analogues as biochemical probes and potential therapeutics”, Biochem. Soc. Trans., 35(2):356-363 (2007). [cited by applicant]
Booth, R.J., et al., “Polymer-Supported Quenching Reagents for Parallel Purification,” J. Am. Chem. Soc., 119: 4882-6 (1997). [cited by applicant]
Borch, R.F., et al., “The Cyanohydridoborate Anion as a Selective Reducing Agent,” J. Am. Chem. Soc., 93(12): 2897-2904 (1971). [cited by applicant]
Bowlin, T.L., et al., “Effect of polyamine depletion in vivo by DL-alpha-difluoromethylornithine on functionally distinct populations of tumoricidal effector cells in normal and tumor-bearing mice”, Cancer Res 46, 5494-… [cited by applicant]
Bowlin, T.L., Hoeper, B.J., Rosenberger, A.L., Davis, G.F. & Sunkara, P.S. Effects of three irreversible inhibitors of ornithine decarboxylase on macrophage-mediated tumoricidal activity and antitumor activity in B16F1 … [cited by applicant]
Bowlin, T.L., McKown, B.J., Davis, G.F. & Sunkara, P.S. Effect of polyamine depletion in vivo by DL-alpha-difluoromethylornithine on functionally distinct populations of tumoricidal effector cells in normal and tumor-be… [cited by applicant]
Boyle, J.O., Meyskens, F.L., Jr., Garewal, H.S. & Gerner, E.W. Polyamine contents in rectal and buccal mucosae in humans treated with oral difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 1, 131-135 (1992). [cited by applicant]
Brand, G., et al., “Cyclopolyamines: Synthesis of Cyclospermidines and Cyclospermines, Analogues of Spermidine and Spermine,” Tetrahedron Lett., 35(46): 8609-12 (1994). [cited by applicant]
Bray, A.M., et al., “Simultaneous Multiple Synthesis of Peptide Amides by the Multipin Method. Application of Vapor-Phase Ammonolysis,” J. Org. Chem., 59: 2197-2203 (1994). [cited by applicant]
Brown, H.C., et al., “Solvomercuration-Demercuration. I. The Oxymercuration-Demercuration of Representative Olefins in an Aqueous System. A Convenient Mild Procedure for the Markovnikov Hydration of the Carbon-Carbon Do… [cited by applicant]
Bruce, et al., “Structure-Activity Relationships of analogues of the Wasp Toxin Philanthotoxin: Non-Competitive Antagonists of Quisqualate Receptors,” Toxicon, 28(11): 1333-1346 (1990). [cited by applicant]
Bukin, Y.V., et al. Effect of prolonged beta-carotene or DL-alpha-tocopheryl acetate supplementation on ornithine decarboxylase activity in human atrophic stomach mucosa. Cancer Epidemiol Biomarkers Prev 4, 865-870 (199… [cited by applicant]
Burns, M.R., et al. Abstract 2006: AMX-513 polyamine depletion therapy inhibits tumor growth and reverses immunosuppression in cancers including MYC-driven neuroblastoma and pancreatic cancer. Cancer Research 77, 2006-2… [cited by applicant]
Burns, M.R., Graminski, G.F., Weeks, R.S., Chen, Y. & O'Brien, T.G. Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor. J Med C… [cited by applicant]
Bussiere, F.I., et al. “Spermine causes loss of innate immune response to Helicobacter pylori by inhibition of inducible nitric-oxide synthase translation”, The Journal of Biological Chemistry 280:2409-2412 (2005). [cited by applicant]
Butler, J.E., et al., “The Physical and Functional Behavior of Capture Antibodies Adsorbed on Polystyrene,” J. Immunol. Meth., 150: 77-90 (1992). [cited by applicant]
Byk, G., et al., “One Pot Synthesis of Unsymmetrically Functionalized Polyamines by a Solid Phase Strategy Starting from their Symmetrical Polyamine-Counterparts,” Tetrahedron Lett., 38(18): 3219-22 (1997). [cited by applicant]
Canizares, F., et al. Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. Clin Cancer Res 5, 2035-2041 (1999). [cited by applicant]
Carbone, P.P., et al. “Bioavailability study of oral liquid and tablet forms of alpha-difluoromethylornithine”, Clin Cancer Res 6, 3850-3854 (2000). [cited by applicant]
Carbone, P.P., et al. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. Cancer Epidemiol Biomarkers Prev 10, 657-661 (2001). [cited by applicant]
Carrington, S., et al., “Inhibition of growth of B16 Murine Melanoma Cells by Novel Spermine Analogs,” Pharm Sci, 2(1): 25-27 (1996). [cited by applicant]
Casara, et al., “Stereospecific Synthesis of (2R,5R)-Hept-6-yne-2,5-diamine: A Potent and Selective Enzyme-activated Irreversible Inhibitor of Ornithine Decarboxylase (Odc),” J. Chem. Perkin Trans., pp. 2201-2207 (1985). [cited by applicant]
Casero RA, “Say What? The Activity of the Polyamine Biosynthesis Inhibitor Difluoromethylornithine in Chemoprevention Is a Result of Reduced Thymidine Pools”, Cancer Discovery, 975-977 (Sep. 2013). [cited by applicant]
Casero, Jr., R.A., et al., “High Specific Induction of Spermidine/Spermins N'-Acetyltransferase in a Human Large Cell Lung Carcinoma,” Biochem. J., 270: 615-20 (1990). [cited by applicant]
Casero, R.A., Jr., et al., “Polyamine metabolism and cancer: treatments, challenges and opportunities”, Nat Rev Cancer 18, 681-695 (2018). [cited by applicant]
Chamaillard, L. et al., “Polyamine Deprivation Prevents the Development of Tumor-Induced Immune Supression,” Br J Cancer, 76:365-370 (1997). [cited by applicant]
Chamaillard, L., Quemener, V., Havouis, R. & Moulinoux, J.P. Polyamine deprivation stimulates natural killer cell activity in cancerous mice. Anticancer Res 13, 1027-1033 (1993). [cited by applicant]
Chan, P.P., et al., “Triplex DNA: Fundamentals, Advances, and Potential Applications for Gene Therapy,” J. Mal. Med., 75: 267-82 (1997). [cited by applicant]
Chang, B.K., et al., “Modulation of polyamine biosynthesis and transport by oncogene transfection”, Biochem Biophys Res Commun 157, 264-270 (1988). [cited by applicant]
Chao, J., et al., “N1-Dansyl-Spermine and N1-(n-octanesulfonyl)-Spermine, Novel Glutamate Receptor Antagonists: Block and Permeation of N-Methyl-D-Aspartate Receptors,” Mol Pharmacol, 51(5): 861-871 (1997). [cited by applicant]
Chaplinski, V., et al., “A Versatile New Preparation of Cyclopropylamines from Acid Dialkylamides,” Angew. Chem. Int. Ed. Engl., 35(4): 413-4 (1996). [cited by applicant]
Chaturvedi, R., et al. “Induction of polyamine oxidase 1 by Helicobacter pylori causes macrophage apoptosis by hydrogen peroxide release and mitochondrial membrane depolarization”, The Journal of Biological Chemistry, 2… [cited by applicant]
Chen, et al., “Combination therapy with 2-difluoromethylomithine and polyamine transport inhibitor against murine squamous cell carcinoma”, Int. J. Cancer, 2006, vol. 118, pp. 2344-2349. [cited by applicant]
Chen, Y., Megosh, L.C., Gilmour, S.K., Sawicki, J.A. & O'Brien, T.G. K6/ODC transgenic mice as a sensitive model for carcinogen identification. Toxicol Lett 116, 27-35 (2000). [cited by applicant]
Claverie, N. & Mamont, P.S. Comparative antitumor properties in rodents of irreversible inhibitors of L-ornithine decarboxylase, used as such or as prodrugs. Cancer Res 49, 4466-4471 (1989). [cited by applicant]
Coni, S., et al. Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation. Cell Death Dis 11, 1045 (2020). [cited by applicant]
Cullis, P. et al., “Probing the mechanism of transport and compartmentalisation of polyamines in mammalian cells,” Chemistry & Biology, 6(10): 717-729 (1999). [cited by applicant]
Danzin et al., “α-Allenyl putrescine, an enzyme-activated irreversible inhibitor of bacterial and mammalian ornithine decarboxylases,” Federation of European Biochemical Societies, vol. 174, No. 2, pp. 275-278 (1984). [cited by applicant]
Danzin, C. & Persson, L. L-ornithine-induced inactivation of mammalian ornithine decarboxylase in vitro. Eur J Biochem 166, 45-48 (1987). [cited by applicant]
Danzin, et al., α-Ethynyl and α-Vinyl Analogues of Ornithine as Enzyme-Activated Inhibitors of Mammalian Ornithine Decarboxylase, J. Med. Chem., vol. 24, pp. 16-20 (1980). [cited by applicant]
Davis, R.H., Lieu, P. & Ristow, J.L. Neurospora mutants affecting polyamine-dependent processes and basic amino acid transport mutants resistant to the polyamine inhibitor, alpha-difluoromethylornithine. Genetics 138, 6… [cited by applicant]
De Clercq, E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther 128, 509-518 (2010). [cited by applicant]
Dempcy, R.O., et al., “Design and Synthesis of Ribonucleic Guanidine: A Polycationic Analog of RNA,” Proc. Natl. Acad. Sci. U.S.A, 93: 4326-30 (1996). [cited by applicant]
Devraj, R., et al., “A Versatile Solid Phase Synthesis of Lavendustin A and Certain Biologically Active Analogs,” J. Org. Chem., 61 :9368-73 (1996). [cited by applicant]
Dhainaut, et al., “New Purines and Purine Analogs as Modulators of Multidrug Resistance,” J Med Chem, 39:4099-4108 (1996). [cited by applicant]
Dhingra, K., et al. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 55, 3060-3067 (1995). [cited by applicant]
DiGiovanni, J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 54, 63-128 (1992). [cited by applicant]
Dimery, I.W., et al. Polyamine metabolism in carcinoma of the oral cavity compared with adjacent and normal oral mucosa. Am J Surg 154, 429-433 (1987). [cited by applicant]
DiPasquale, A., et al., “Epidermal Growth Factor Stimulates Putrescine Transport and Ornithine Decarboxylase Activity in Cultures Human Fibroblasts,” Exp Cell Res, 116: 317-323 (1978). [cited by applicant]
Doll, M., et al., “Synthesis of Tenuilobine, a Bis-polyamine Alkaloid from Oncinotis tenuiloba, and Its Transamidation to Isotenuilobine,” Helv. Chim. Acta, vol. 79, No. 2, pp. 541-547 (1996). [cited by applicant]
Douglas, S.P., et al., “Polymer-Supported Solution Synthesis of Oligosaccharides Using a Novel Versatile Linker for the Synthesis of D-Mannopentaose, a Structural Unit of D-Mannans of Pathogenic Yeasts,” J. Am. Chem. So… [cited by applicant]
Drug Fut., 16: 1165-1166 (1991). [cited by applicant]
Dyshlovoy, S.A., et al. Proteomic profiling of germ cell cancer cells treated with aaptamine, a marine alkaloid with antiproliferative activity. J Proteome Res 11, 2316-2330 (2012). [cited by applicant]
Eisenburg, T. et al. “Cardioprotection and lifespan extension by the natural polyamine spermidine”, Nature Medicine, 22(12):1428-1438 (2016). [cited by applicant]
Eriksson, C., Masaki, N., Yao, I., Hayasaka, T. & Setou, M. Maldi Imaging Mass Spectrometry-A Mini Review of Methods and Recent Developments. Mass Spectrom (Tokyo) 2, S0022 (2013). [cited by applicant]
Erwin, B.G. & Pegg, A.E. Uptake of alpha-difluoromethylornithine by mouse fibroblasts. Biochem Pharmacol 31, 2820-2823 (1982). [cited by applicant]
European Extended Search Report for Application No. 17770923.5 dated Oct. 15, 2019. [cited by applicant]
Evageliou, N.F., et al. Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression. Clin Cancer Res 22, 4391-4404 (2016). [cited by applicant]
Evans, et al. “Spermine-directed immunosuppression of cervical carcinoma cell sensitivity to a majority of lymphokineactivated killer lymphocyte cytotoxicity”,. Nat. Immun., 14:157-163 (1995). [cited by applicant]
Felschow, D.M. et al., “Selective Labeling of Cell-Surface Polyamine-Binding Proteins on Leukemic and Solid-Tumor Cell Types Using a New Polyamine Photoprobe,” Biochem J, 328(3): 889-895 (1997). [cited by applicant]
Felschow, D.M., et al., “Photoaffinity Labeling of a Cell Surface Polyamine Binding Protein,” J. Biol. Chem., 270(48): 28705-11 (1995). [cited by applicant]
Fillingame et al., “Increased cellular levels of spermidine or spermine are required for optimal DNA synthesis in lymphocytes activated by concanavalin A,” Proc. Nat. Acad. Sci. USA, vol. 72, No. 10, pp. 4042-4045 (1975… [cited by applicant]
Final Office Action for U.S. Appl. No. 11/050,789, titled: “Hydrophobic Polyamine Analogs And Methods For Their Use,” mailed Jun. 25, 2007. [cited by applicant]
Final Office Action for U.S. Appl. No. 11/050,789, titled: “Hydrophobic Polyamine Analogs And Methods For Their Use,” mailed Aug. 4, 2008. [cited by applicant]
Final Office Action for U.S. Appl. No. 11/062,481, titled: “Hydrophobic Polyamine Analogs And Methods For Their Use,” mailed Nov. 20, 2007. [cited by applicant]
Fiori L.M et al. “Implication of the polyamine system in mental disorders”, J. Psychiatry Neurosci., 33(2):102-110 (2008). [cited by applicant]
Flemming, S.A., “Chemical Reagents in Photoaffinity Labeling,” Tetrahedron, 51(46): 12479-520 (1995). [cited by applicant]
Flescher, E., Bowlin, T.L. & Talal, N. Polyamine oxidation down-regulates IL-2 production by human peripheral blood mononuclear cells. J Immunol 142, 907-912 (1989). [cited by applicant]
Flescher, E., et al., “Increased Polyamines May Downregulate Interleukin 2 Production in Rheumatoid Arthritis,” J. Clin. Invest., 83: 1356-62 (1989). [cited by applicant]
Fujimura, K., Wang, H., Watson, F. & Klemke, R.L. KRAS Oncoprotein Expression Is Regulated by a Self-Governing eIF5A-PEAK1 Feed-Forward Regulatory Loop. Cancer Res 78, 1444-1456 (2018). [cited by applicant]
Furka, A., “General Method for Rapid Synthesis of Multicomponent Peptide Mixtures,” Int. J. Peptide Protein Res., 37: 487-93 (1991). [cited by applicant]
Furumitsu, Y., et al., “Levels of Urinary Polyamines in Patients with Rheumatoid Arthritis,” J. Rheumatology, 20(10): 1661-5 (1993). [cited by applicant]
Gaines, D.W., Friedman, L. & McCann, P.P. Apparent ornithine decarboxylase activity, measured by 14CO2 trapping, after frozen storage of rat tissue and rat tissue supernatants. Anal Biochem 174, 88-96 (1988). [cited by applicant]
Gallop, M.A., et al., “Applications of Combinatorial Technologies to Drug Discovery. Background and Peptide Combinatorial Libraries.,” J. Med. Chem., 37(9): 1233-51 (1994). [cited by applicant]
Gamble, L.D., et al. Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. Sci Transl Med 11(2019). [cited by applicant]
Ganem, B., “New Chemistry of Naturally Occuring Polyamines,” Acc. Chem. Res., 15: 290-8 (1982). [cited by applicant]
Garewal, H.S., Sloan, D., Sampliner, R.E. & Fennerty, B. Ornithine decarboxylase assay in human colorectal mucosa. Methodologic issues of importance to quality control. Int J Cancer 52, 355-358 (1992). [cited by applicant]
Geerts, D., et al. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer 126, 2012-2024 (2010). [cited by applicant]
Gensler, H.L. Prevention by alpha-difluoromethylornithine of skin carcinogenesis and immunosuppression induced by ultraviolet irradiation. J Cancer Res Clin Oncol 117, 345-350 (1991). [cited by applicant]
Gerner, E.W. & Meyskens, F.L., Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4, 781-792 (2004). [cited by applicant]
Gerner, E.W., Garewal, H.S., Emerson, S.S. & Sampliner, R.E. Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with alpha-difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 3… [cited by applicant]
Gervais, A., et al. “Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency”, Breast Cancer Res., 7:R326-335 (2005). [cited by applicant]
Gervais, A., et al. “Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells”, Anticancer Research 25, 2177-2185 (2005). [cited by applicant]
Gilad GM et al., “Novel Polyamine Derivatives and Neuroprotective Agents”, Pharmacology and Experimental Therapeutics, 291(1):39-43 (1999). [cited by applicant]
Gilmour, et al., “Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Anti-Tumor Efficacy of PD-1 Blockade”, Mol Cancer Ther (2020). [cited by applicant]
Gobert, A.P., et al. Hypusination Orchestrates the Antimicrobial Response of Macrophages. Cell Rep 33, 108510 (2020). [cited by applicant]
Golub et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring,” Science, vol. 286, pp. 531-537 (1999). [cited by applicant]
Goodnow, Jr., R., et al., “Synthesis of Glutamate Receptor Antagonist Philanthotoxin-433 (PhTX-433) and its Analogs,” Tetrahedron Lett., 46(9): 3267-86 (1990). [cited by applicant]
Goodnow, Jr., R.A., et al., “Oligomer Synthesis and DNA/RNA Recognition Properties of a Novel Oligonucleotide Backbone Analog: Glucopyranosyl Nuclei Amide (GNA),” Tetrahedron Lett., 38(18): 3199-3202 (1997). [cited by applicant]
Goodnow, Jr., R.A., et al., “Synthesis of Thymine, Cytosine, Adenine, and Guanine Containing N-Fmoc Protected Amino Acids: Building Blocks for Construction of Novel Oligonucleotide Backbone Analogs,” Tetrahedron Lett., … [cited by applicant]
Gordon, D.W., et al., “Reductive Alkylation on a Solid Phase: Synthesis of a Piperazinedione Combinatorial Library,” Bioorg. Med. Chem. Lett., 5(1): 47-50 (1995). [cited by applicant]
Gordon, E.M., et al., “Applications of Combinatorial Technologies to Drug Discovery. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions,” J. Med. Chem., 37(10): 1385-1401 (1994). [cited by applicant]
Gorus, F., et al., “Applications of Bio-and Chemiluminescence in the Clinical Laboratory,” Clin. Chem., 25(4): 512-9 (1979). [cited by applicant]
Green, A.C. et al., “Polyamine Amides are Neuroprotective in Cerebellar Granule Cell Cultures Challenged with Excitatory Amino Acids,” Brain Research 717/1-2: 135-146 (1996). [cited by applicant]
Griffin, C.A., et al. Phase I trial and pharmacokinetic study of intravenous and oral alpha-difluoromethylornithine. Invest New Drugs 5, 177-186 (1987). [cited by applicant]
Ha, H.C. et al. “The Natural Polyamine Spermine Functions Directly as a Free Radical Scavenger,” Proc Natl Acad Sci USA, 95: 11140-11145 (1998). [cited by applicant]
Ha, H.C. et al., “The Role of Polyamine Catabolismin Polyamine Analogue-Induced Programmed Cell Death,” Proc. Natl. Acad. Sci., 94: 11557-62 (1997). [cited by applicant]
Haber, M., et al: “Abstract IA13: Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies” Cancer Research, Jul. 31, 2020 (Jul. 31, 2020), 4 pages. [cited by applicant]
Haegele, K.D., Alken, R.G., Grove, J., Schechter, P.J. & Koch-Weser, J. Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin Pharmacol Ther 30, 210-217 (1981). [cited by applicant]
Hahm, H.A., et al. Phase I study of N(1),N(11)-diethylnorspermine in patients with non-small cell lung cancer. Clin Cancer Res 8, 684-690 (2002). [cited by applicant]
Han, H. et al., “Liquid-Phase Combinatorial Synthesis,” Proc. Natl. Acad. Sci. USA, 92: 6419-23 (1995). [cited by applicant]
Hanauske-Abel, H. M. et al., “Detection of a Sub-Set of Polysomal mRNAs Associated with Modulation of Hypusine Formation at the G1-S Boundary Proposal of a Role for elf-5A in onset of DNA Replication,” FEBS Lett., 366: … [cited by applicant]
Hatanaka, T., et al., “Ion pair skin transport of a zwitterionic drug, cephalexin”, J Control Release 66, 63-71 (2000). [cited by applicant]
Hayashi, S. et al. “Ornithine Decarboxylase Antizyme: A Novel Type of Regulatory Protein,” Trends In Biochemical Sciences, 21: 27-30 (1996). [cited by applicant]
Hayes, C.S. et al., “Polyamine-Blocking Therapy Reverses Immunosuppression in the Tumor Microenvironment,” Cancer Immunology Research, vol. 2; No. 3; 274-285 (2014). [cited by applicant]
Hayes, C.S., Burns, M.R. & Gilmour, S.K. Polyamine blockade promotes antitumor immunity. Oncoimmunology 3, e27360 (2014). [cited by applicant]
Hayes, C.S., et al. A prolonged and exaggerated wound response with elevated ODC activity mimics early tumor development. Carcinogenesis 32, 1340-1348 (2011). [cited by applicant]
Heller, J.S. et al. “Induction of a Protein Inhibitor to Ornithine Decarboxylase by the End Products of Its Reaction,” Proc Natl Acad Sci USA, 73: 1858-1862 (1976). [cited by applicant]
Herbst, R.S., et al. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 9, 4108-41… [cited by applicant]
Hernandez, A.S. et al., “Solid -Supported tert-Alkoxycarbonylation Reagents for Anchoring of Amines During Solid Phase Organic Synthesis,” J. Org. Chem., 62: 3153-7 (1997). [cited by applicant]
Herrera-Ornelas, L., et al. A comparison of ornithine decarboxylase and S-adenosylmethionine decarboxylase activity in human large bowel mucosa, polyps, and colorectal adenocarcinoma. J Surg Res 42, 56-60 (1987). [cited by applicant]
Higashi et al., “Structural and Functional Relationship among Diamines in Terms of Inhibition of Cell Growth,” J. Biochem., vol. 136, pp. 533-539 (2004). [cited by applicant]
Hixson, L.J., et al. Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol Biomarkers Prev 2, 369-374 (1993). [cited by applicant]
Holley, J., et al., “Uptake and Cytotoxicity of Novel Nitroimidazole-Polyamine Conjugates in Ehrlich Ascites Tumour Cells,” Biochem. Pharmacol., 43(4): 763-9 (1992). [cited by applicant]
Holley, J.L., et al., “Targeting of Tumor Cells and DNA by a Chlorambucil-Spermidine Conjugates,” Cancer Res., 52: 4190-5 (1992). [cited by applicant]
http://www.msnbc.msn.com/id/7320341, Hair follicles offer source of nerve stem cells Mouse whisker cells turned into neurons, researchers say, Hair follicles offer source of nerve stem cells, 2005, p. 1. [cited by applicant]
Huber, M. et al., “2,2'-Dithiobis (N-ethyl-spermine-5-carboxamide) Is a High Affinity, Membrane-Impermeant Antagonist of the Mammalian Polyamine Transport System,” J. Biol. Chem., 271(44): 27556-63 (1996). [cited by applicant]
Huber, M. et al., “Antiproliferative Effect of Spermine Depletion by N-Cyclohexyl-1,3-diaminopropane in Human Breast Cancer Cells,” Cancer Res., 55: 934-43 (1995). [cited by applicant]
Huff, J.R., “HIV protease: a novel chemotherapeutic target for AIDS,” J. Med. Chem., 34(8): 2305-14 (1991). [cited by applicant]
Hynd, et al., “Inhibition of Polyamine Synthesis Alters Hair Follicle Function and Fiber Composition,” The Society for Investigative Dermatology, vol. 106, No. 2, pp. 249-253 (1996). [cited by applicant]
Hyvönen, M.T., Keinänen, T. & Alhonen, L. Assay of Ornithine Decarboxylase and Spermidine/Spermine N1-acetyltransferase Activities. Bio-protocol 4, e1301 (2014). [cited by applicant]
International Preliminary Examination Report for International Application No. PCT/US2002/00347, titled: “Hydrophobic Polyamine Analogs and Methods For Their Use,” mailed Oct. 17, 2003. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017/023250, titled: “Bioavailable Polyamines,” mailed Oct. 4, 2018. [cited by applicant]
International Search Report and Written Opinion dated Jun. 21, 2017, for Application No. PCT/US2017/023250, titled: “Bioavailable Polyamines.”. [cited by applicant]
International Search Report for International Application No. PCT/US2002/00347, titled: “Hydrophobic Polyamine Analogs and Methods For Their Use,” mailed Dec. 4, 2002. [cited by applicant]
Ishiwata, K., Abe, Y., Matsuzawa, T. & Ido, T. Tumor uptake studies of D,L-[5-14C]ornithine and D,L-2-difluoromethyl [5-14C]ornithine. Int J Rad Appl Instrum B 15, 119-122 (1988). [cited by applicant]
Ivaturi, V.D. et al., “Enhanced permeation of methotrexate in vitro by ion pair formation with L-arginine”, J Pharm Sci 98, 3633-3639 (2009). [cited by applicant]
Iwanowicz, E.J et al., “Preparation of N,N'-Bis-tert-Butoxycarbonylthiourea,” Synthetic Comm., 23(10): 1443-5 (1993). [cited by applicant]
Janda, K.D. et al., “Combinatorial Chemistry: A Liquid-Phase Approach,” Meth. Enzymol., 267: 234-47 (1996). [cited by applicant]
Janne, J. & Williams-Ashman, H.G. Mammalian ornithine decarboxylase: activation and alteration of physical behaviour by thiol compounds. Biochem J 119, 595-597 (1970). [cited by applicant]
Janne, J. & Williams-Ashman, H.G. On the purification of L-ornithine decarboxylase from rat prostate and effects of thiol compounds on the enzyme. J Biol Chem 246, 1725-1732 (1971). [cited by applicant]
Janne, J. et al., “Polyamines in Rapid Growth and Cancer,” Biochim Biophys Acta 4 73: 241-293 (1978). [cited by applicant]
Jasnis, M.A. et al., “Polyamines Prevent DFMO-Mediated Inhibition of Angiogenesis,” Cancer Lett., 79: 39-43 (1994). [cited by applicant]
Kahana, et al., “Isolation of cloned cDNA encoding mammalian ornithine decarboxylase,” Proc. Natl. Acad. Sci. USA, vol. 81, pp. 3645-3649 (1984). [cited by applicant]
Kaiser, E. et al., “Color Test for Detection of Free Terminal Amino Groups in the Solid-Phase Synthesis of Peptides,” Anal. Biochem., 34(2): 595-8 (1970). [cited by applicant]
Kakinuma, Y. et al., “Cloning of the Gene Encoding a Putative Serine/Threonine Protein Kinase Which Enhances Spermine Uptake In Saccharomyces Cerevisiae,” Biochem. Biophys. Res. Comm., 216(3): 985-92 (1995). [cited by applicant]
Kano, Y., et al. Increased blood spermine levels decrease the cytotoxic activity of lymphokine-activated killer cells: a novel mechanism of cancer evasion. Cancer Immunol Immunother 56, 771-781 (2007). [cited by applicant]
Kanth, J.V.B., et al., “Selective Reduction of Carboxylic Acids into Alcohols Using NaBH [cited by applicant]
Karahalios, P. et al., “The Effect of Acylated Polyamine Derivative on Polyamine Uptake Mechanism, Cell Growth, and Polyamine Pools in [cited by applicant]
Kashiwagi, K. et al., “Isolation of Polyamine Transport-Deficient Mutants of [cited by applicant]
Kaur N. et al. “Designing the Polyamine Pharmacophore: Influence of N-Substituents on the Transport Behavior of Polyamine Conjugates”, J. Med. Chem., 51:2551-2560 (2008). [cited by applicant]
Kendrick et al., “2,2-Difluoro-5-hexyne-1,4-diamine: A Potent Enzyme-Activated Inhibitor of Ornithine Decarbocylase,” J. Med. Chem., vol. 32, pp. 170-173 (1989). [cited by applicant]
Keough, M.P., Hayes, C.S., DeFeo, K. & Gilmour, S.K. Elevated epidermal ornithine decarboxylase activity suppresses contact hypersensitivity. J Invest Dermatol 131, 158-166 (2011). [cited by applicant]
Khan, A., et al. Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas. Nat Commun 12, 971 (2021). [cited by applicant]
Khan, N., Quemener, V. et al., “Characterization of Polyamine Transport pathways”, in Neuropharmacology of Polyamines (Carter, C., ed.), Academic, San Diego, pp. 37-60 (1994). [cited by applicant]
Kilpelainen, P.T. & Hietala, O.A. Activation of rat brain ornithine decarboxylase by GTP. Biochem J 300 ( Pt 2), 577-582 (1994). [cited by applicant]
Klier, H., et al. Isolation and structural characterization of different isoforms of the hypusine-containing protein elF-5A from HeLa cells. Biochemistry 34, 14693-14702 (1995). [cited by applicant]
Kobayashi, et al., “Control Spermidine and Spermine Levels in Rat Tissues by trans-4-Methylcyclohexylamine, a Spermidine-Synthase Inhibitor,” Biol. Pharm. Bull., vol. 28, No. 4, pp. 569-573 (2005). [cited by applicant]
Kohl, N.E., Gee, C.E. & Alt, F.W. Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science 226, 1335-1337 (1984). [cited by applicant]
Koike, M. et al., “Blocking effect of 1-naphthyl acetyl spermine on Ca [cited by applicant]
Koone, et al., “A Mode of Action for Butylated Hydroxytoluene-Mediated Photoprotection,” Journal of Investigative Derm., vol. 87., No. 3, pp. 343-347 (1986). [cited by applicant]
Kossorotow, A. et al., “Regulatory Effects of Polyamines on Membrane-Bound Acetylcholinesterase,” Biochem J, 144: 21-27 (1974). [cited by applicant]
Kozumbo, et al., “Inhibition by 2(3)-tert-Butyl-4-hydroxyanisole and Other Antioxidants of Epidermal Ornithine Decarboxylase Activity Induced by 12-O-Tetradecanoylphorbol-13-acetate,” Cancer Research, vol. 43, pp. 2555-… [cited by applicant]
Krapcho, A.P. et al., “Mono-Protected Diamines. N-tert-Butoxycarbonyl-a, w-Alkanediamines from α,ω-Alkanediamines,” Syn Comm, 20: 2559-2564 (1990). [cited by applicant]
Kremmer, T. et al., “Comparative Studies on the Polyamine Metabolism and DFMO Treatment of MCF-7 and MDA-MB-231 Breast Cancer Cell Lines and Xenografts,” Anticancer Res., 11: 1807-14 (1991). [cited by applicant]
Kruczynski, A., et al. F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity. Leukemia 27, 2139-2148 (2013). [cited by applicant]
Lack, N.A., et al. A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther 77, 427-436 (2005). [cited by applicant]
Laguzza, B.C., et al., “A New Protecting Group For Amines: Synthesis of Anticapsin from LTyrosine,” Tetrahedron Lett., 22(16): 1483-6 (1981). [cited by applicant]
Lakanen et al., Synthesis and Biochemical Evaluation of Adenosylspermidine, a Nucleoside-Polyamine Adduct Inhibitor of Spermidine Synthase, J. Med. Chem., vol. 38, pp. 2714-2727 (1995). [cited by applicant]
Lakanen, J.R., et al., “α-Methyl Polyamines: Metabolically Stable Spermidine and Spermine Mimics Capable of Supporting Growth in Cells Depleted of Polyamines,” J. Med. Chem., 35: 724-34 (1992). [cited by applicant]
Lam, K.S., “Application of Combinatorial Library Methods in Cancer Research and Drug Discovery,” Anti-Cancer Drug Des., 12: 145-67 (1997). [cited by applicant]
LaMuraglia, G.M., Lacaine, F. & Malt, R.A. High ornithine decarboxylase activity and polyamine levels in human colorectal neoplasia. Ann Surg 204, 89-93 (1986). [cited by applicant]
Lan, L., Hayes, C.S., Laury-Kleintop, L. & Gilmour, S.K. Suprabasal induction of ornithine decarboxylase in adult mouse skin is sufficient to activate keratinocytes. J Invest Dermatol 124, 602-614 (2005). [cited by applicant]
Lee, J., “Facile Preparation of Cyclopropylamines from Carboxamides,” J. Org. Chem., 62: 1584-5 (1997). [cited by applicant]
Leveque, J. et al., “The Gastrointestinal Polyamine Source Depletion Enhances DFMO induced Polyamine Depletion in MCF-7 Human Breast Cancer Cells [cited by applicant]
Levin, V.A., Csejtey, J. & Byrd, D.J. Brain, CSF, and tumor pharmacokinetics of alpha-difluoromethylornithine in rats and dogs. Cancer Chemother Pharmacol 10, 196-199 (1983). [cited by applicant]
Li, Y. et al., “Comparative Molecular Field Analysis-Based Predictive Model of Structure-Function Relationships of Pilyamine Transport Inhibitors in L1210 Cells,” Cancer Res, 57: 234-239 (1997). [cited by applicant]
Li, Y. et al., “Synthesis and Antitumor Evaluation of a Highly Potent Cytotoxic DNA Cross-Linking Polyamine Analogue, 1, 12-Diaziridinyl-4,9-diazadodecane,” J. Med. Chem., 39: 339-41 (1996). [cited by applicant]
Liao, X., Liang, W., Wiedmann, T., Wattenberg, L. & Dahl, A. Lung distribution of the chemopreventive agent difluoromethylornithine (DFMO) following oral and inhalation delivery. Exp Lung Res 30, 755-769 (2004). [cited by applicant]
Libby, P.R., Henderson, M., Bergeron, R.J. & Porter, C.W. Major increases in spermidine/spermine-N1-acetyltransferase activity by spermine analogues and their relationship to polyamine depletion and growth inhibition in… [cited by applicant]
Linsalata, M., et al. Prognostic value of tissue polyamine levels in human colorectal carcinoma. Anticancer Res 22, 2465-2469 (2002). [cited by applicant]
Lipinski CA, et al. “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings”, Adv. Drug Deliv. Rev., 46(1-3):3-26 (2001). [cited by applicant]
Liu, L., et al. Polyamine-modulated expression of c-myc plays a critical role in stimulation of normal intestinal epithelial cell proliferation. Am J Physiol Cell Physiol 288, C89-99 (2005). [cited by applicant]
Lloyd-Williams, P., “Convergent Solid-Phase Peptide Synthesis,” Tetrahedron, 49(48): 11065-133 (1993). [cited by applicant]
Loiseau, P.M., Czok, M., Chauffert, O., Bourass, J. & Letourneux, Y. Studies on lipidomimetic derivatives of alpha-difluoromethylornithine (DFMO) to enhance the bioavailability in a Trypanosoma B. brucei murine trypanos… [cited by applicant]
Lowe, et al., “Antiinflammatory Drug Effects on Ultraviolet Light-Induced Epidermal Ornithine Decarboxylase and DNA Synthesis,” The Journal of Investigative Dermatology, vol. 74, pp. 418-420 (1980). [cited by applicant]
Lu, J. Triethylenetetramine pharmacology and its clinical applications. Mol Cancer Ther 9, 2458-2467 (2010). [cited by applicant]
Luk, G.D., Goodwin, G., Marton, L.J. & Baylin, S.B. Polyamines are necessary for the survival of human small-cell lung carcinoma in culture. Proc Natl Acad Sci U S A 78, 2355-2358 (1981). [cited by applicant]
Maddox, A.M., Freireich, E.J., Keating, M.J., Frasier-Scott, K.F. & Haddox, M.K. Alterations in human circulating and bone marrow mononuclear cell polyamine levels in hematologic malignancies as a consequence of difluor… [cited by applicant]
Maddox, A.M., Keating, M.J., McCredie, K.E., Estey, E. & Freireich, E.J. Phase I evaluation of intravenous difluoromethylornithine—a polyamine inhibitor. Invest New Drugs 3, 287-292 (1985). [cited by applicant]
Maher, S. et al., “Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic,” 2 Mvanced Drug Delivery Reviews, Elsevier, v. 61, No. 15, Dec. 17, 2009, pp. 1427-1499. [cited by applicant]
Maillard, L., et al., “Percutaneous Delivery of the Gax Gene Inhibits Vessel Stenosis in a rabbit Model of Balloon Angioplasty,” Cardiovasc. Res., 35: 536-46 (1997). [cited by applicant]
Manni, A., Mauger, D., Gimotty, P. & Badger, B. Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer. Clin Cancer Res 2, 1901-1906 (1996). [cited by applicant]
Marton, L.J., et al. The relationship of polyamines in cerebrospinal fluid to the presence of central nervous system tumors. Cancer Res 36, 973-977 (1976). [cited by applicant]
Marton, L.J., et al., “Polyamines as Targets for Therapeutic Intervention,” Annu. Rev. Pharmacol. Toxicol., 35: 55-91 (1995). [cited by applicant]
Maryam Karimi-Jafari et al: “Creating Cocrystals: A Review of Pharmaceutical Cocrystal Preparation Routes and Applications”, Crystal Growth & Design, vol. 18, No. 10, Oct. 3, 2018 (Oct. 3, 2018), pp. 6370-6387. [cited by applicant]
Matsufuji, S. et al., “Reading Two Bases Twice: Mammalian Antizyme Frame Shifting in Yeast,” EMBO Journal, 15: 1360-1370 (1996). [cited by applicant]
Matthews, H.R., “Polyamines, Chromatin Structure and Transcription,” BioEssays, 15: 561-566 (1993). [cited by applicant]
McWilliams, M.L. et al., “Characterization of the Ototoxicity of Difluoromethylornithine and Its Enantiomers,” Toxicological Sciences, vol. 56; 124-132 (2000). [cited by applicant]
Medina, C.B., et al. “Metabolites released from apoptotic cells act as tissue messengers”, Nature 580, 130-135 (2020). [cited by applicant]
Melchiorre C. et al. “Polyamines in Drug Discovery: From the Universal Template Approach to the Multitarget-Directed Ligand Design Strategy”, J. Med. Chem., 53:5906-5914 (2010). [cited by applicant]
Messenger, “The Control of Hair Growth: An Overview,” The Society for Investigative Dermatology, vol. 101, No. 1, 4S-9S (1993). [cited by applicant]
Messing, E.M., et al. Low-dose difluoromethylornithine and polyamine levels in human prostate tissue. J Natl Cancer Inst 91, 1416-1417 (1999). [cited by applicant]
Metcalf, et al., “Catalytic Irreversible Inhibition of Mammalian Ornithine Decarboxylase (E.C. 4.1.1.17) by Substrate and Product Analogues,” Journal of the American Chemical Society, vol. 100, No. 8, pp. 2551-2553 (197… [cited by applicant]
Meyskens, F.L., Jr., et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1, 32-38 (2008). [cited by applicant]
Meyskens, F.L., Jr., et al. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst 86, 1122-1130 (1994). [cited by applicant]
Meyskens, F.L., Jr., et al. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 90, 1212-1218 (1998). [cited by applicant]
Milord, F., Loko, L., Ethier, L., Mpia, B. & Pepin, J. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 87,… [cited by applicant]
Minarini A. et al. “Synthetic polyamines activating autophagy: Effects on cancer cell death”, European J. Medicinal Chem., 67:359-366 (2013). [cited by applicant]
Misquith, A., et al. In vitro evaluation of TLR4 agonist activity: formulation effects. Colloids Surf B Biointerfaces 113, 312-319 (2014). [cited by applicant]
Mitchell, M.F., et al. Polyamine measurements in the uterine cervix. J Cell Biochem Suppl 28-29, 125-132 (1997). [cited by applicant]
Mitchell, M.F., et al., “Difluoromethylornithine (DFMO) treatment is Associated with Decreased CD Blood Vessel Counts in Cervical Intraepithelial Neoplasia (CIN),” Proceedings AACR, 39 (Abstract#600) : 88 (1998). [cited by applicant]
Moulinoux, J.P. et al., “Biological Significance of Circulating Polyamines in Oncology,” Cell Mal Biol, 37: 773-783 (1991). [cited by applicant]
Moulinoux, J.P. et al., “Inhibition of growth of the U-251 Human Glioblastoma in Nude Mice by Polyamine Deprivation,” Anticancer Res, 11: 175-180 (1991). [cited by applicant]
Moya, E. et al., “Synthesis and Neuropharmacological properties of Arthropod Polyamine Amide Toxins,” Neuropharmacology of Polyamines (Carter, C., ed.), Academic, San Diego, pp. 167-184 (1994). [cited by applicant]
Moyano, et al., “Inhibition of Omithine Decarbocylase by the Isomers of 1,4-dimethylputrescine,” J. Med. Chem., vol. 33, No. 7, pp. 1969-1974 (1990). [cited by applicant]
Murakami, Y. et al., “Ornithine Decarboxylase Is Degraded be the 26S Proteasome Without Ubiquitination,” Nature, 360: 597-599 (1992). [cited by applicant]
Muramoto, K., “Preparation and Characterization of Photoactivatable Heterobifunctional Fluorescent Reagents,” Agric. Biol. Chem., 48(11): 2695-9 (1984). [cited by applicant]
Murray-Stewart T. et al. “The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase=1 (LSD1) inhibitor in human acute myeloid leukemia cell lines”, Amino Acids,… [cited by applicant]
Muth, A., et al. “Polyamine transport inhibitors: design, synthesis, and combination therapies with difluoromethylornithine”, J Med Chem 57, 348-363 (2014). [cited by applicant]
Na-Bangchang, K., et al. The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness. Eur J Clin Pharmacol 60, 269-278 (2004). [cited by applicant]
Nagarajan, S., et al., “Chemistry of Naturally Occuring Polyamines. 10. Nonmetabolizable Derivatives of Spermine and Spermidine,” J. Org. Chem., 51: 4856-61 (1986). [cited by applicant]
Nagarajan, S., et al., “Chemistry of Naturally Occurring Polyamines. II. Unsaturated Spermidine and Spermine Derivatives,” J. Org. Chem., 52: 5044-6 (1987). [cited by applicant]
Nakanishi, et al., “Philantotoxin-433 (PhTX-433), a non-competitive glutamate receptor inhibitor,” Pure Appl. Chem., 62: 1223-1230 (1990). [cited by applicant]
Nakaoka, T., et al., “Inhibition of Rat Vascular Smooth Muscle Proliferation [cited by applicant]
Nancarrow, et al., “Dynamic expression of omithine decarboxylase in hair growth,” Mechanisms of Development, vol. 84, pp. 161-164 (1999). [cited by applicant]
Nesher, G. et al., “The [cited by applicant]
Neubert, R. “Ion pair transport across membranes”, Pharm Res 6(9), 743-747 (1989). [cited by applicant]
Neubert, R. et al., “Ion pair approach of ampicillin using in vitro methods”, Pharm Acta Helv 65, 186-188 (1990). [cited by applicant]
Newton, G.L. et al., “Effect of Polyamine-Induced Compaction and Aggregation of DNA—A Major Factor in Radioprotection of Chromatin under Physiological Conditions,” Radiation Research, 145: 776-80 (1996). [cited by applicant]
Nilam, M., et al. A Label-Free Continuous Fluorescence-Based Assay for Monitoring Ornithine Decarboxylase Activity with a Synthetic Putrescine Receptor. SLAS Discov 22, 906-914 (2017). [cited by applicant]
Nilsson, J.A., et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 7, 433-444 (2005). [cited by applicant]
Nilsson, J.L.G et al., “Fibrin-Stabilizing Factor Inhibitors” Acta Pharmaceutica Suecica, 8(4): 497-504 (1971). [cited by applicant]
Nishiki, Y., et al. Characterization of a novel polyclonal anti-hypusine antibody. Springerplus 2, 421 (2013). [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/753,291, consisting of 13 pages. Date Mailed Apr. 30, 2019. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/823,150, consisting of 39 pages. Date Mailed Sep. 7, 2021. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 11/050,789, titled: “Hydrophobic Polyamine Analogs And Methods For Their Use,” mailed Dec. 6, 2006. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 11/050,789, titled: “Hydrophobic Polyamine Analogs And Methods For Their Use,” mailed Jan. 4, 2008. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 11/062,481, titled: “Hydrophobic Polyamine Analogs And Methods For Their Use,” mailed Apr. 23, 2007. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/753,291, consisting of 4 pages. Date Mailed Jan. 23, 2020. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/823,150, “Bioavailable Polyamines” Date Mailed Mar. 21, 2022. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 10/296,259, titled: “Hydrophobic Polyamine Analogs And Methods For Their Use,” mailed Sep. 28, 2004. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 11/062,481, titled: “Hydrophobic Polyamine Analogs And Methods For Their Use,” mailed May 28, 2008. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 13/047,297, titled: “Hydrophobic Polyamine Analogs And Methods For Their Use,” mailed Aug. 17, 2011. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 13/047,297, titled: “Hydrophobic Polyamine Analogs And Methods For Their Use,” mailed Dec. 13, 2011. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 15/753,291, titled: “Bioavailable Polyamines,” mailed Jan. 23, 2020. [cited by applicant]
Notification of Transmittal of The International Search Report and the Written Opinion of the International Searching Authority, or the Declaration for International Application No. PCT/US2021/052788, “Combination Drug … [cited by applicant]
O'Brien, T.G. The induction of ornithine decarboxylase as an early, possibly obligatory, event in mouse skin carcinogenesis. Cancer Res 36, 2644-2653 (1976). [cited by applicant]
O'Brien, T.G., Hietala, O., O'Donnell, K. & Holmes, M. Activation of mouse epidermal tumor ornithine decarboxylase by GTP: evidence for different catalytic forms of the enzyme. Proc Natl Acad Sci U S A 84, 8927-8931 (19… [cited by applicant]
O'Brien, T.G., Megosh, L.C., Gilliard, G. & Soler, A.P. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res 57, 2630-2637 (1997). [cited by applicant]
Origanti, S. et al., “Ras transformation of RIE-1 cells activates cap-independent translation of ornithine decarboxylase: regulation by the Raf/MEK/ERK and phosphatidylinositol 3-kinase pathways”, Cancer Res 67, 4834-48… [cited by applicant]
O'Sullivan MC et al. “Dibenzusuberyl substituted polyamines and analogs of clomipramine as effective inhibitors of trypanothione reductase; molecular docking, and assessment of trypanocidal activities”, Bioorganic & Med… [cited by applicant]
Pan, X., et al. Cerebrospinal Fluid Spermidine, Glutamine and Putrescine Predict Postoperative Delirium Following Elective Orthopaedic Surgery. Sci Rep 9, 4191 (2019). [cited by applicant]
Parchment, R. E. et al., “Polyamine Oxidation, Programmed Cell Death, and Regulation of Melanoma in the Murine Embryonic Limb,” Cancer Res., 49: 6680-6 (1989). [cited by applicant]
Pegg, A.E. & Feith, D.J. Polyamines and neoplastic growth. Biochem Soc Trans 35, 295-299 (2007). [cited by applicant]
Pendyala, L., Creaven, P.J. & Porter, C.W. Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a phase I chemoprevention clinical trial. Cancer Epidemiol Biomarkers Prev 2, … [cited by applicant]
Peralta Soler, et al., “Modulation of Murine Hair Follicle Function by Alterations in Ornithine Decarboxylase Activity,” The Society for Investigative Dermatology, vol. 106, No. 5, pp. 1108-1113 (1996). [cited by applicant]
Persson, L. et al., “Curative Effect of d, 1-2-Difluoromethylornithine on Mice Bearing Mutant L1210 Leukemia Cells Deficient in Polyamine Uptake,” Cancer Res, 48: 4807-4811 (1998). [cited by applicant]
Pfitzner, K.E., et al., “Sulfoxide-Carbodiimide Reactions. I. A Facile Oxidation of Alcohols,” J. Am. Chem. Soc., 87(24): 5661-9 (1965). [cited by applicant]
Pietilä, et al., “Activation of Polyamine Catabolismprofoundly Alters Tissue Polyamine Pools and Affects Hair Growth and Female Fertility in Transgenic Mice Overexpressing Spermidine/Spermine N [cited by applicant]
Pietilä, et al., “Relation of Skin Polyamines to the Hairless Phenotype in Transgenic Mice Overexpressing Spermidine/Spermine N [cited by applicant]
Pohjanpelto, P. “Putrescine Transport is Greatly Increased in Human Fibroblasts Initiated to Prolifarete,” J Cell Biol, 68: 512-520 (1976). [cited by applicant]
Porter, C.W. et al., “Aliphatic Chain Length Specificity of the Polyamine Transport System in Ascites L1210 Leukemia Cells,” J Cancer Res, 44: 126-128 (1984). [cited by applicant]
Porter, C.W., et al., “Antitumor Activity of N [cited by applicant]
Poulin, R., Lu, L., Ackermann, B., Bey, P. & Pegg, A.E. Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine. Characterization of sequences at the inhibitor and co… [cited by applicant]
Probst et al., “Ornithine decarboxylase activity in relation to DNA synthesis in mouse interfollicular epidermis and hair follicles,” Biochim Biophys Acta, vol. 407, No. 2, pp. 147-157 (1975). [cited by applicant]
Puleston, D.J., et al. Polyamines and eIF5A Hypusination Modulate Mitochondrial Respiration and Macrophage Activation. Cell Metab 30, 352-363 e358 (2019). [cited by applicant]
Qarawi, M. et al. “Optimization of the MMT Assay for B16 Murine Melanoma Cells and CE Its Application in Assessing Growth Inhibition by Polyamines and Novel Polyamine Conjugates,” Pharm Sci., vol. 3, (5/6): 235-239 (199… [cited by applicant]
Quemener, V. et al., “Polyamine Deprivation Enhances Antitumoral Efficacy of Chemotherapy,” Anticancer Res, 12: 1447-1454 (1992). [cited by applicant]
Quemener, V. et al., “Polyamine Deprivation: A New Tool in Cancer Treatment,” Anticancer Res., 14: 443-8 (1994). [cited by applicant]
Raditsch, M. et al., “Polyamine Spider Toxins and Mammalian N-Methyl-D-Aspartate Receptors. Structural Basis for Chemical Blocking and Binding of Argiotoxin 636,” Eur J Biochem, 240: 416-426 (1996). [cited by applicant]
Raines, D. E., et al., “Potential-Dependent Phase Partitioning of Fluorescent Hydrophobic Ions in Phospholipid Vesicles,” J. Membrane Biol., 82: 241-7 (1984). [cited by applicant]
Rajeev, K.G., et al., “Conformationally Restrained Chiral Analogues of Spermine: Chemical Synthesis and Improvements in DNA Triplex Stability,” J. Org. Chem., 62: 5169-73 (1997). [cited by applicant]
Ranganathan, R. S., et al., “Novel Analogues of Nucleoside 3',5'-Cyclic Phosphates. I. 5'-Mono-and Dimethyl Analogs of Adenosine 3',5'-Cyclic Phosphate,” J. Org. Chem., 39(3): 290-8 (1974). [cited by applicant]
Ransom, R.W. et al., “Cooperative Modulation of [ [cited by applicant]
Ray, R.M., Bhattacharya, S., Bavaria, M.N., Viar, M.J. & Johnson, L.R. Spermidine, a sensor for antizyme 1 expression regulates intracellular polyamine homeostasis. Amino Acids 46, 2005-2013 (2014). [cited by applicant]
Relyea et al., “Potent Inhibition of Ornithine Decarboxylase by β, γ Unsaturated Substrate Analogs,” Biochemical and Biophysical Research Communications, vol. 67, No. 1, pp. 392-402 (1975). [cited by applicant]
Rink, H., “Solid-Phase Synthesis of Protected Peptide Fragments Using a Trialkoxy-Diphenyl-Methylester Resin,” Tetrahed. Lett., 28(33): 3787-90 (1987). [cited by applicant]
Romijn, J.C., Verkoelen, C.F. & Splinter, T.A. Problems of pharmacokinetic studies on alpha-difluoromethylornithine in mice. Cancer Chemother Pharmacol 19, 30-34 (1987). [cited by applicant]
Rossi T. et al. “Mepacrine Antagonises Tumour Cell Growth Induced by Natural Polyamines”, Anticancer Research, 28:2765-2768 (2008). [cited by applicant]
Russell, D. et al., “Amine Synthesis in Rapidly Growing Systems: Ortithine Decarboxylase Activity in Generating Rat Liver, Chick Embryos, and Various Tumors,” Proc Natl Acad Sci USA, 60(4): 1420-1427 (1968). [cited by applicant]
Saiki R. et al. “In Vitro and in vivo evaluation of polymethylene tetraamine derivatives as NMDA receptor channel blockers”, Bioorganic & Medicinal Chem. Letters, 23:3901-3904 (2013). [cited by applicant]
Salemme, F.R., et al., “Serendipity Meets Precision: The Integration of Structure-Based Drug Design and Combinatorial Chemistry for Efficient Drug Discovery,” Structure, 5(3): 319-24 (1997). [cited by applicant]
Samal, K. et al., “AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport,” International … [cited by applicant]
Sarhan, S. et al., “The Gastrointestial Tract as Polyamine Source for Tumor Growth,” Anticancer Res, 9: 215-224 (1989). [cited by applicant]
Sasaki, Y. et al., “Solid-Phase Synthesis and Biological Properties of .psi.[CH [cited by applicant]
Saulnier Sholler, G.L., et al. “, Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma”, PLoS One 10, e0127246 (2015). [cited by applicant]
Scalabrino, G. et al., “Polyamines in Mammalian Tumors. Part I,” Adv Cancer Res, 35:151-268 (1981). [cited by applicant]
Scalabrino, G. et al., “Polyamines in Mammalian Tumors. Part II,” Adv Cancer Res, 36:1-102 (1982). [cited by applicant]
Scalabrino, G., et al. Levels of activity of the polyamine biosynthetic decarboxylases as indicators of degree of malignancy of human cutaneous epitheliomas. J Invest Dermatol 74, 122-124 (1980). [cited by applicant]
Schallenberg, E. E., et al., “Ethyl Thioltrifluoroacetate As An Acetylating Agent with Particular Reference to Peptide Synthesis,” J. Am. Chem. Soc., 77: 2779-83 (1955). [cited by applicant]
Schechter, P.J. et al., “Clinical Aspects of Inhibition of Ornithine Decarboxylase with Emphasis on Therapeutic Trials of Eflornithine (DFMO) in Cancer and Protozoan Diseases,” Inhibition of Polyamine Metabolism. Biolog… [cited by applicant]
Schultheiss, N. et al., “Pharmaceutical Cocrystals and Their Physicochemical Properties”, Cryst Growth Des 9, 2950-2967 (2009). [cited by applicant]
Seiler N., et al., “Polyamines and apoptosis”, J. Cell. Mal. Med. 9(3):623-642 (2005). [cited by applicant]
Seiler, N. et al., “Polyamine Transport in Mammalian Cells,” Int J Biochem, 22: 211-218 (1990). [cited by applicant]
Seiler, N. et al., “Polyamine Transport in Mammalian Cells. An update,” Int J Biochem, 28(8): 843-861 (1996). [cited by applicant]
Seiler, N., “Functions of Polyamine Acetylation,” Can Pharmacol, 65: 2024-2035 (1987). [cited by applicant]
Seiler, N., “Polyamine Oxidase, Properties and Functions,” Progress in Brain Res, 106: 333-344 (1995). [cited by applicant]
Senanayake T. et al. “Design of polyamine-based therapeutic agents: new targets and new directions”, Essay Biochem., 46:77-94 (2013). [cited by applicant]